PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer.

[1]  F. Bertucci,et al.  DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  N. Pavlidis,et al.  BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside , 2022, Cancers.

[3]  E. Kotteas,et al.  CD24: A Novel Target for Cancer Immunotherapy , 2022, Journal of personalized medicine.

[4]  K. Seow,et al.  The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review , 2022, International journal of molecular sciences.

[5]  Xiaona Chen,et al.  seRNA PAM controls skeletal muscle satellite cell proliferation and aging through trans regulation of Timp2 expression synergistically with Ddx5 , 2022, Aging cell.

[6]  R. Mostoslavsky,et al.  DNA repair as a shared hallmark in cancer and ageing , 2022, Molecular oncology.

[7]  A. Louie,et al.  Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. , 2022, Seminars in cancer biology.

[8]  S. Domchek,et al.  Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. , 2022, The Lancet. Oncology.

[9]  M. Somerfield,et al.  Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Yundong He,et al.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials , 2022, Signal Transduction and Targeted Therapy.

[11]  F. Rassool,et al.  Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use , 2022, Cancers.

[12]  G. Huls,et al.  CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma , 2022, Biomedicines.

[13]  J. Zell,et al.  BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms , 2022, Cancers.

[14]  S. H. van der Burg,et al.  Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. , 2022, European journal of cancer.

[15]  Zhu Xu,et al.  Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS. , 2022, Molecular cell.

[16]  B. Zhu,et al.  Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy. , 2022, Advanced drug delivery reviews.

[17]  K. Luo,et al.  Poly(ADP-ribosylation) of P-TEFb by PARP1 disrupts phase separation to inhibit global transcription after DNA damage , 2022, Nature Cell Biology.

[18]  D. Muoio,et al.  Functions of ADP-ribose transferases in the maintenance of telomere integrity , 2022, Cellular and Molecular Life Sciences.

[19]  Y. Piao,et al.  Circular RNA dehydrodolichyl diphosphate synthase facilitated triple‐negative breast cancer progression via miR‐362‐3p/DDX5 axis , 2022, Environmental toxicology.

[20]  M. Kizaki,et al.  CD24 is a surrogate for ‘immune‐cold’ phenotype in aggressive large B‐cell lymphoma , 2022, The journal of pathology. Clinical research.

[21]  Elizabeth L Siegler,et al.  CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities , 2022, Molecular therapy oncolytics.

[22]  G. Gupta,et al.  Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection , 2022, Nature Communications.

[23]  B. Paschal,et al.  Reconstitution of the DTX3L-PARP9 complex reveals determinants for high affinity heterodimerization and multimeric assembly. , 2022, The Biochemical journal.

[24]  Yanshu Li,et al.  PAK5 promotes RNA helicase DDX5 sumoylation and miRNA-10b processing in a kinase-dependent manner in breast cancer , 2021, Cell Reports.

[25]  M. Oya,et al.  The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. , 2021, European urology.

[26]  S. Ramalingam,et al.  JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer , 2021, Cancer.

[27]  Tarek Barbar,et al.  Tumor Lysis Syndrome. , 2021, Advances in chronic kidney disease.

[28]  G. Peng,et al.  Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. , 2021, Trends in cancer.

[29]  Christine E. Brown,et al.  Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy , 2021, Frontiers in Immunology.

[30]  F. Cardoso,et al.  PARP inhibitors coming of age , 2020, Nature Reviews Clinical Oncology.

[31]  S. Delaloge,et al.  Survival benefits of PARP inhibitors in advanced breast cancer: a mirage? , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  G. Miller,et al.  Regulation and modulation of antitumor immunity in pancreatic cancer , 2020, Nature Immunology.

[33]  G. Kristiansen,et al.  Novel insights into the function of CD24: A driving force in cancer , 2020, International journal of cancer.

[34]  J. Valle,et al.  Pancreatic cancer , 2020, The Lancet.

[35]  Zhenhua Zhou,et al.  The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma , 2020, EBioMedicine.

[36]  K. Yin,et al.  Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer , 2019, Journal of Immunotherapy for Cancer.

[37]  S. Khan,et al.  Current understanding of tumor lysis syndrome , 2019, Hematological oncology.

[38]  V. Malladi,et al.  Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21. , 2019, Molecular cell.

[39]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[40]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[41]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[42]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[43]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[44]  Qiaojun He,et al.  PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3 , 2018, Cancer Immunology Research.

[45]  Kathleen A Cronin,et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.

[46]  Kian Behbakht,et al.  PARP inhibitors: Clinical utility and possibilities of overcoming resistance. , 2017, Gynecologic oncology.

[47]  M. Shlomchik,et al.  Tissue‐Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells , 2017, Immunity.

[48]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[49]  Ziying Liu,et al.  PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes , 2017, Genes & development.

[50]  F. Bock,et al.  New directions in poly(ADP‐ribose) polymerase biology , 2016, The FEBS journal.

[51]  E. Giovannetti,et al.  FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. , 2016, World journal of gastroenterology.

[52]  J. Nie,et al.  Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells* , 2015, The Journal of Biological Chemistry.

[53]  Tao Jiang,et al.  DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway , 2015, Cancer science.

[54]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  F. Wilson,et al.  Tumor lysis syndrome: new challenges and recent advances. , 2014, Advances in chronic kidney disease.

[56]  Tesshi Yamada,et al.  CHFR Protein Regulates Mitotic Checkpoint by Targeting PARP-1 Protein for Ubiquitination and Degradation* , 2012, The Journal of Biological Chemistry.

[57]  Wenqing Xu,et al.  Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. , 2012, Genes & development.

[58]  F. Martínez.  Analysis of Gene Expression and Gene Silencing in Human Macrophages , 2012, Current protocols in immunology.

[59]  C. Pui,et al.  The tumor lysis syndrome. , 2011, The New England journal of medicine.

[60]  Li Yang,et al.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. , 2010, Trends in immunology.

[61]  Yang Liu,et al.  CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. , 2009, Trends in immunology.

[62]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[63]  Ping Wang,et al.  A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. , 2009, Journal of immunological methods.

[64]  F. Fuller-Pace.  DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation , 2006, Nucleic acids research.

[65]  K. Bomsztyk,et al.  Protocol for the fast chromatin immunoprecipitation (ChIP) method , 2006, Nature Protocols.

[66]  W. Daughaday,et al.  Tumor secretion of growth factors. , 1991, Endocrinology and metabolism clinics of North America.